NUCC-390 is a chemokine (C-X-C motif) receptor 4 (CXCR4) agonist.1 It induces calcium mobilization in C8161 melanoma cells expressing CXCR4 when used at a concentration of 10 ?M, an effect that can be prevented by the CXCR4 antagonist AMD3100 . NUCC-390 (0.0625, 0.125, and 0.25 ?M) increases axon length in cultured rat spinal cord motor neurons.2 In vivo, NUCC-390 (26 mg/kg per day) restores gastrocnemius muscle compound muscle action potentials (CMAPs) in a mouse model of sciatic nerve crush injury. It also restores CMAPs in a mouse model of neuroparalysis induced by Papuan taipan (O. scutellatus) venom.3
1.Mishra, R.K., Shum, A.K., Platanias, L.C., et al.Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonistsSci. Rep.6:301551-9(2016) 2.Zanetti, G., Negro, S., Megighian, A., et al.A CXCR4 receptor agonist strongly stimulates axonal regeneration after damageAnn. Clin. Transl. Neurol.6(12)2395-2402(2019) 3.Stazi, M., D'Este, G., Mattarei, A., et al.An agonist of the CXCR4 receptor accelerates the recovery from the peripheral neuroparalysis induced by Taipan snake envenomationPLoS Negl. Trop. Dis.14(9)e0008547(2020)